Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 1
2008 1
2010 1
2011 1
2014 1
2015 1
2017 1
2018 3
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT. Pan Z, et al. Among authors: honigberg la. ChemMedChem. 2007 Jan;2(1):58-61. doi: 10.1002/cmdc.200600221. ChemMedChem. 2007. PMID: 17154430 No abstract available.
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho C, Paul R. Cummings JL, et al. Among authors: honigberg la. Neurology. 2018 May 22;90(21):e1889-e1897. doi: 10.1212/WNL.0000000000005550. Epub 2018 Apr 25. Neurology. 2018. PMID: 29695589 Free PMC article. Clinical Trial.
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, Quartino A, Clayton D, Mortensen D, Bittner T, Ho C, Rabe C, Schauer SP, Wildsmith KR, Fuji RN, Suliman S, Reiman EM, Chen K, Paul R. Salloway S, et al. Among authors: honigberg la. Alzheimers Res Ther. 2018 Sep 19;10(1):96. doi: 10.1186/s13195-018-0424-5. Alzheimers Res Ther. 2018. PMID: 30231896 Free PMC article. Clinical Trial.
Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.
Yaspan BL, Williams DF, Holz FG, Regillo CD, Li Z, Dressen A, van Lookeren Campagne M, Le KN, Graham RR, Beres T, Bhangale TR, Honigberg LA, Smith A, Henry EC, Ho C, Strauss EC; MAHALO Study Investigators. Yaspan BL, et al. Among authors: honigberg la. Sci Transl Med. 2017 Jun 21;9(395):eaaf1443. doi: 10.1126/scitranslmed.aaf1443. Sci Transl Med. 2017. PMID: 28637922 Clinical Trial.
Identification of substrates of human protein-tyrosine phosphatase PTPN22.
Wu J, Katrekar A, Honigberg LA, Smith AM, Conn MT, Tang J, Jeffery D, Mortara K, Sampang J, Williams SR, Buggy J, Clark JM. Wu J, et al. Among authors: honigberg la. J Biol Chem. 2006 Apr 21;281(16):11002-10. doi: 10.1074/jbc.M600498200. Epub 2006 Feb 6. J Biol Chem. 2006. PMID: 16461343 Free article.
Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.
Spellman DS, Wildsmith KR, Honigberg LA, Tuefferd M, Baker D, Raghavan N, Nairn AC, Croteau P, Schirm M, Allard R, Lamontagne J, Chelsky D, Hoffmann S, Potter WZ; Alzheimer's Disease Neuroimaging Initiative; Foundation for NIH (FNIH) Biomarkers Consortium CSF Proteomics Project Team. Spellman DS, et al. Among authors: honigberg la. Proteomics Clin Appl. 2015 Aug;9(7-8):715-31. doi: 10.1002/prca.201400178. Epub 2015 Apr 24. Proteomics Clin Appl. 2015. PMID: 25676562 Free PMC article.
12 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page